Christopher Ryan Sullivan sold $1.4M of Avalo Therapeutics (AVTX)

Executed Aug 17, disclosed Aug 19, 2 days later.

Value, as filed

$1.4M

68,976 sh across 2 lots

Executed

Aug 17

the trade date, as filed

Disclosed

Aug 19

2 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

Christopher Ryan Sullivan Chief Financial Officer profile →

Christopher Ryan Sullivan (Chief Financial Officer) filed 7 Form 4 reports in the trailing twelve months (0 purchases, 7 sales), most often in Avalo Therapeutics, Inc. (AVTX). The largest single filing was $1.4M of AVTX (68,976 sh across 2 lots, as filed), executed Aug 17.

The name

AVTX

Avalo Therapeutics, Inc. AVTX · Healthcare · 11 filings in 24 months ticker →

Healthcare · Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Christopher Ryan Sullivan in AVTX

AVTXSALE Avalo Therapeutics, Inc. $202K
12,394 sh × $16.33
Exec Sep 16
Filed Sep 18 · 4:10 PM ET AVTXSALE Avalo Therapeutics, Inc. $179K
10,185 sh × $17.62
Exec Sep 10
Filed Sep 11 · 4:10 PM ET AVTXSALE Avalo Therapeutics, Inc. $449K
18,606 sh × $24.12
Exec May 7
Filed May 11 · 5:30 PM ET AVTXSALE Avalo Therapeutics, Inc. $893K
44,300 sh across 4 lots
Exec May 6
Filed May 7 · 5:30 PM ET AVTXSALE Avalo Therapeutics, Inc. $223K
16,915 sh across 2 lots
Exec Apr 29
Filed May 1 · 5:30 PM ET AVTXSALE Avalo Therapeutics, Inc. $231K
13,679 sh across 2 lots
Exec Apr 1
Filed Apr 3 · 5:30 PM ET